A new Galleri blood test detected 75% of cancers without current screening options, with over half found in early stage I or ...

Discover groundbreaking research on pulmonary fibrosis and a potential new treatment target that could revolutionize lung ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...

DelveInsight's Liposarcoma Market Insights report includes a comprehensive understanding of current treatment practices, ...

Breast cancer remains the leading cause of cancer deaths among women worldwide. In Africa, where health systems are under strain, the World Health Organization (WHO) warns that without decisive action ...

Liposarcoma market growth is driven by increasing awareness and earlier diagnosis, expanding the pool of treatable patients. Advances in molecular profiling and targeted therapies ...